Ticker
ACST

Price
0.71
Stock movement down
-0.02 (-2.73%)
Company name
Acasti Pharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
31.68M
Ent value
17.50M
Price/Sales
2436.89
Price/Book
0.32
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-36.60%
3 year return
-50.23%
5 year return
-40.30%
10 year return
-43.11%
Last updated: 2023-01-31

DIVIDENDS

ACST does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2436.89
Price to Book0.32
EV to Sales1346.20

FINANCIALS

Per share

Loading...
Per share data
Current share count44.61M
EPS (TTM)-0.37
FCF per share (TTM)-0.32

Income statement

Loading...
Income statement data
Revenue (TTM)13.00K
Gross profit (TTM)0.00
Operating income (TTM)-18.39M
Net income (TTM)-16.52M
EPS (TTM)-0.37
EPS (1y forward)-0.52

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-141446.15%
Profit margin (TTM)-127038.46%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash34.93M
Net receivables859.00K
Total current assets37.51M
Goodwill12.96M
Intangible assets69.81M
Property, plant and equipment0.00
Total assets120.91M
Accounts payable3.73M
Short/Current long term debt520.00K
Total current liabilities3.81M
Total liabilities20.75M
Shareholder's equity100.16M
Net tangible assets17.39M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-14.31M
Capital expenditures (TTM)23.00K
Free cash flow (TTM)-14.32M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-16.49%
Return on Assets-13.66%
Return on Invested Capital-16.48%
Cash Return on Invested Capital-14.29%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.74
Daily high0.75
Daily low0.68
Daily Volume116K
All-time high325.60
1y analyst estimate2.26
Beta1.10
EPS (TTM)-0.37
Dividend per share-
Ex-div date-
Next earnings date13 Feb 2023

Downside potential

Loading...
Downside potential data
ACSTS&P500
Current price drop from All-time high-99.78%-14.91%
Highest price drop-99.90%-56.47%
Date of highest drop12 Dec 20229 Mar 2009
Avg drop from high-84.92%-11.49%
Avg time to new high75 days13 days
Max time to new high2380 days1805 days
COMPANY DETAILS
ACST (Acasti Pharma Inc) company logo
Marketcap
31.68M
Marketcap category
Small-cap
Description
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Employees
0
Investor relations
-
SEC filings
CEO
Janelle D'Alvise
Country
USA
City
Laval
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 25, 2023
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 24, 2023
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.
January 17, 2023
Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage specialty pharma company with drug delivery technologies and dru...
January 17, 2023
LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 13, 2023
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 5, 2023
Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript November 14, 2022 Operator: Good day, and welcome to the Acasti Pharma Second Quarter 2023 Earnings Event Call. All participants will ...
December 29, 2022
LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
December 28, 2022
LAVAL, Québec, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
December 22, 2022
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, special...
November 14, 2022
Next page